A Phase 1 Study to Assess the Pharmacokinetics, Safety, Tolerability and immunogenicity of Fremanezumab (formerly TEV-48125) doses (225 mg, 675mg and 900 mg) in Japanese and Caucasian Healthy Subjects
CEPHALALGIA(2017)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要